問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
王耀東
下載
2025-09-22 - 2029-03-18
Condition/Disease
• Safety: Number of participants experiencing adverse events (AEs) and serious adverse events (SAEs). • Efficacy: Objective response rate (ORR).
Test Drug
Dato-DXd Rilvegostomig Xinruize
Participate Sites9Sites
Recruiting9Sites
2023-05-10 - 2025-04-30
Participate Sites7Sites
Recruiting6Sites
Terminated1Sites
2023-09-30 - 2028-08-31
Participate Sites2Sites
Recruiting2Sites
2024-01-22 - 2028-12-31
Participate Sites12Sites
Recruiting12Sites
2024-10-31 - 2026-12-31
Participate Sites8Sites
Recruiting8Sites
2018-11-02 - 2028-12-31
Division of Thoracic Medicine
2021-02-01 - 2026-03-18
Participate Sites10Sites
Not yet recruiting2Sites
Recruiting7Sites
2018-12-01 - 2026-03-31
Division of Hematology & Oncology
2024-09-01 - 2038-12-31
2021-03-01 - 2027-02-28
Participate Sites4Sites
Recruiting4Sites
全部
